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the chosen level divided by the total
number of IOP times 100%. SPSS version
7.0 (IBM,Armonk,NY,USA)was used
for the analysis.
Forty-six patients (91 eyes; mean
follow-up time, 11 years) were included.
The mean rate of MD progression was
0.26 dB/year. Sight-related quality of
life (MD worse than 15 dB in both eyes
(Peters et al. 2015)) would be affected in
41%of the patients (19 of 46) during the
expected lifetime. The MD rate in eyes
with significant visual field progression
was 0.53 dB/year (46% of eyes). Com-
paring mean rates of MD progression
with the fraction (%) of IOP measure-
ments <16 and <15 mmHg showed a
significant difference for < 15 mmHg
(0.13 dB/year (31 eyes) versus 0.33 dB/
year (60 eyes), p = 0.04)).
Comparing mean rates of MD pro-
gression with the fraction (%) of IOP
measurements lower than 16 and
15 mmHg, respectively (Fig. 1), showed
a significant difference for a discrimi-
natory level of 15 mmHg. The rates of
MD progression calculated by linear
regression correlated significantly to
the fraction of treated pressures that
were lower than 15 mmHg (Fig. 1;
r = 0.22; p = 0.04; Fig. 1).
In conclusion, the study shows that
the mean rate of MD progression in
patients with NTG was low (0.26 dB/
year) but with a high interpatient
variability. In comparison, the rate of
MD progression in untreated NTG in
whites has been shown to be 0.41
(Anderson et al. 2001) and 0.36 dB/
year (Heijl et al. 2009) but with large
interpatient variability in both studies
like in this study. The rate of MD
progression in whites with treated
NTG has been shown to be 0.35 dB/
year after 5 years (Ahrlich et al. 2010)
and between 0.2 and 0.4 dB/year after
9 years (Anderson et al. 2003).
In this study, the rate of MD
progression in the eyes with significant
visual field progression was 0.53 dB/
year (46% of the eyes). This is in
accordance with the observation that
only 34% of the eyes in this study have
IOP measurements predominantly on
or below the calculated target pressure
(14 mmHg). Intensifying treatment in
patients with progressive NTG in clin-
ical care therefore seems advisable.
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E xfoliation glaucoma ( XFG) isdifferentiated from primary open-
angle glaucoma (POAG) by its clinical
and histopathological features (Vesti &
Kivel€a 2000). Elevation of intraocular
pressure (IOP) in EXG is associated
with an increase in aqueous outflow
resistance. It may be caused by
endothelial dysfunction, exfoliation
material, pigment liberation from the
iris and ciliary epithelia, or a combina-
tion of these factors. At the time of
diagnosis, IOP in EXG is higher than
in POAG and shows more fluctuation
(Konstas et al. 1997). The peak IOP
occurs most frequently outside the
office hours. A single measurement of
Fig. 1. Rate of progression of visual fields (n = 91 eyes) calculated by linear regression of mean
defect (MD) over time. Each regression parameter with a significance level below or above 5% is
indicated by a diamond or a triangle, respectively, and plotted against the number of visits with
pressure measurements below 15 mmHg (regression coefficient 0.004  0.002, r = 0.22, p = 0.04).
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the, typically with, Goldmann appla-
nation tonometry (GAT) is not suffi-
cient to estimate the average IOP level
(Konstas et al. 1997). One way to solve
this problem is to use of an electro-
magnetic rebound tonometer requiring
no anaesthesia that has been found to
be suitable for home and self-tonome-
try (Tarkkanen et al. 2010; Sakamoto
et al. 2014;. In UK, 73% of glaucoma
patients learned to use this method
(Pronin et al. 2017). We have found
that if the patient is well motivated, age
is not an obstacle.
Our patient is an 84-year-old male
with bilateral exfoliation diagnosed at
the age of 69 years. Over the years, his
IOP remained at lower teens. He
underwent bilateral cataract surgery
with intraocular lens implantation at
the age of 80 years. His visual acuities,
optic discs and visual fields were nor-
mal. Chamber angles were wide open
but showed exfoliation deposits and
pigmentation. Exfoliation material
also was present at the pupillary bor-
der. Recently, the IOP measured on
three different occasions using GAT
was on average 14/36 mmHg.
Although we detected no injury to
the optic disc, if left untreated, he
would be at risk of IOP-related com-
plications, including central retinal
vein occlusion. Hence, we prescribed
preservation-free combination of
bimatoprost and timolol once a day
to the left eye. The target IOP was set
at 20 mmHg or less. As he was
interested in self-tonometry, he began
to control his IOP at home once a
week using iCare HOME rebound
tonometer (iCare Finland, Helsinki,
Finland). The metre stores each result
but the patient cannot see the IOP.
Initially, the senior author (AT) veri-
fied the accuracy of his measurements
against GAT. He always measured the
IOP several times a day and we
recorded the highest reading. During
12 months, the IOP was controlled on
60 days. At the end of the project, no
change in the left optic disc could be
detected.
The IOP fluctuation was marked in
both eyes (Fig. 1). In the right eye, the
IOP varied between 5 and 16 mmHg,
with a mean of 11 mmHg [standard
deviation (SD), 2.7]. In the left eye, the
fluctuation was more pronounced and
the IOP varied between 12 and 33
mmHg with a mean of 20 (SD, 4.9)
mmHg. The IOP exceeded the target
IOP of 20 mmHg 22 times of 57
(38%).
Elevated IOP is the main and the
only modifiable risk factor for optic
nerve damage in glaucoma. Self-tono-
metry is useful in the diagnosis and
therapy of especially those types of
glaucoma with known tendency to high
IOP and prominent fluctuation, such as
EXG. Should there be progression of
glaucomatous damage, the ophthal-
mologist can verify with confidence
whether the target IOP is too high or
whether the treatment is insufficient to
maintain the IOP at the target level
between office visits. We recommend
self-tonometry for wider use in manag-
ing glaucoma.
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O ptogenetics, or the use of light-sensitive proteins to observe and
control events in living cells, is consid-
ered one of the most groundbreaking
innovations in neuroscience in recent
years. By bestowing light sensitivity to
retinal cells typically downstream of
retinal damage/dysfunction, optogenet-
ics has the potential to treat many
diseases regardless of patient-specific
mutations. This is a major advantage
when (1) the mutation is unknown, (2)
gene replacement has not yet proven
feasible and (3) retinal neurons and
supporting cells have undergone signif-
icant anatomical and functional remod-
elling.
Despite several strengths with appli-
cations being explored in clinical trials,
the use of optogenetics in ophthalmol-
ogy prompts several considerations.
Principally, most nonmodified micro-
bial opsins used for ophthalmic appli-
cations require intense light for
activation (between 1014 and 1017 pho-
tons/cm2/s). For example, blue light
stimulation requiredby themost applied
opsin (Channelrhodopsin-2) may vari-
ably exceed the safety threshold of
artificial radiation for the human retina
(International Commission on Non-
Ionizing Radiation Protection 2013).
Intense light stimulation is required for
two reasons: (1) the relatively low
expression level of opsins in transduced
retina when compared to native visual
pigment (due to toxic and immunologic
concerns) as well as (2) the relatively
weak signal generation of microbial ion
channels or pumps (typically type 1
opsins)when compared to theG-protein
coupled signal amplification of human
rhodopsin (type 2 opsins).
One approach to overcome the reli-
ance on potentially damaging wave-
lengths of light is the creation of
modified red-shifted opsins (Douar
et al. 2016) allowing for activation at
safer spectra. Another approach is the
creation of photopharmacologic and
optogenetic actuators with higher
sensitivities. For example, engineered
chemical photoswitches that bestow
light sensitivity to endogenous trans-
membrane channels can be activated at
4 9 1013 photons/cm2/s. It is also pos-
sible engineer and/or apply more effi-
cient opsins such as the modified human
melanopsin (opto-mGluR6) conferring
light sensitivity to retinal ganglion cells
(RGCs) at 6 9 1012 photons/cm2/s
(van Wyk et al. 2015) and human rod
opsin conferring light sensitivity to reti-
nal bipolar cells at 1012 photons/cm2/
s.(Kapetanovic et al. 2017) An addi-
tional tool is to employ light-projecting
goggles to capture the visual scene,
amplify the light intensity of various
features and project the image onto the
retina at wavelengths optimized for
opsin activation.(Goetz et al. 2013)
Such goggles may also preserve the loss
of meaningful visual mapping when
nonphotoreceptor elements (bipolar
cells or RGCs) generate the light-trans-
duction signalling cascade. This is
accomplished by projecting light in spa-
tiotemporally altered patterns meaning-
ful to various subpopulations of RGCs.
Further limitations implicit in cur-
rent optogenetic approaches are those
pertaining to viral-based gene therapy.
Briefly, these include the variable effi-
ciency of viral transduction, non-spe-
cific opsin expression and off-target
viral effects due to leaky promoters,
the stability of expression with the
potential for cellular toxicity due to
gene product buildup and others. How-
ever, significant advancements have
been made in viral-based gene therapy
including the first FDA approved gene
therapy (for Leber’s congenital amau-
rosis) on 12/19/2017.
A significant hurdle to the long-term
efficacy of optogenetics yet to be
addressed is retinal remodelling. This
occurs in chronic dystrophic and degen-
erative diseases where the structure and
function of remaining neuronal sig-
nalling pathways are disrupted. Even
when prior considerations are
addressed, targeting neurons that are
mis-wired and/or functionally damaged
limits meaningful visual gains. Retinal
remodelling remains an issue of con-
cern for all genetic, prosthetic and/or
regenerative therapies for the retina
and will need to be investigated further
as a field.
Optogenetics remains a remarkable
neuroscientific tool with incredible
promise for ophthalmology. This letter
is not intended to discourage the use of
optogenetics in a clinical setting, but
rather to illuminate surmountable hur-
dles and to raise awareness for design-
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